Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin LymphomasBusiness Wire • 09/04/20
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid LeukemiaBusiness Wire • 09/03/20
Gilead (GILD) Down 9.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 08/29/20